Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Xavier Anglaret

Showing results (91-100 of 161) with videos related to

Pageof 17
Sort By:
Annals of Internal Medicine|July 22, 2009
When to start antiretroviral therapy in resource-limited settingsRochelle P Walensky, Lindsey L Wolf, Robin Wood, et al.
The New England Journal of Medicine|September 15, 2006
Cost-effectiveness of HIV treatment in resource-poor settings--the case of Côte d'IvoireSue J Goldie, Yazdan Yazdanpanah, Elena Losina, et al.
Diagnostic Microbiology and Infectious Disease|August 19, 2015
Identifying patients infected with hepatitis B virus in sub-Saharan Africa: potential for misclassificationAnders Boyd, Sarah Maylin, Raoul Moh, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|June 26, 2013
Increasing rate of TAMs and etravirine resistance in HIV-1-infected adults between 12 and 24 months of treatment: the VOLTART cohort study in Côte d'Ivoire, West AfricaEugène Messou, Marie-Laure Chaix, Delphine Gabillard, et al.
Antiviral Therapy|July 20, 2012
Could early antiretroviral therapy entail more risks than benefits in sub-Saharan African HIV-infected adults? A model-based analysisXavier Anglaret, Callie A Scott, Rochelle P Walensky, et al.
AIDS (London, England)|March 23, 2016
Early antiretroviral therapy initiation in west Africa has no adverse social consequences: a 24-month prospective studyKévin Jean, Serge Niangoran, Christine Danel, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|April 13, 2004
Impact of vital status investigation procedures on estimates of survival in cohorts of HIV-infected patients from Sub-Saharan AfricaXavier Anglaret, Siaka Toure, Gwénola Gourvellec, et al.
AIDS (London, England)|May 9, 2014
WHO guidelines for antiretroviral therapy in serodiscordant couples in sub-Saharan Africa: how many fit?Gérard Kouamé, Christine Danel, Raoul Moh, et al.
Transactions of the Royal Society of Tropical Medicine and Hygiene|October 2, 2019
Hepatitis B virus activity in untreated hepatitis B e antigen-negative human immunodeficiency virus-hepatitis B virus co-infected patients from sub-Saharan AfricaAnders Boyd, Menan Gerard Kouamé, Laura Houghtaling, et al.
Bulletin of the World Health Organization|August 2, 2008
Early loss of HIV-infected patients on potent antiretroviral therapy programmes in lower-income countriesMartin W G Brinkhof, François Dabis, Landon Myer, et al.
Pageof 17

Showing results (91-100 of 161) with videos related to

Sort By:
Pageof 17
Annals of Internal Medicine|July 22, 2009
When to start antiretroviral therapy in resource-limited settingsRochelle P Walensky, Lindsey L Wolf, Robin Wood, et al.
The New England Journal of Medicine|September 15, 2006
Cost-effectiveness of HIV treatment in resource-poor settings--the case of Côte d'IvoireSue J Goldie, Yazdan Yazdanpanah, Elena Losina, et al.
Diagnostic Microbiology and Infectious Disease|August 19, 2015
Identifying patients infected with hepatitis B virus in sub-Saharan Africa: potential for misclassificationAnders Boyd, Sarah Maylin, Raoul Moh, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|June 26, 2013
Increasing rate of TAMs and etravirine resistance in HIV-1-infected adults between 12 and 24 months of treatment: the VOLTART cohort study in Côte d'Ivoire, West AfricaEugène Messou, Marie-Laure Chaix, Delphine Gabillard, et al.
Antiviral Therapy|July 20, 2012
Could early antiretroviral therapy entail more risks than benefits in sub-Saharan African HIV-infected adults? A model-based analysisXavier Anglaret, Callie A Scott, Rochelle P Walensky, et al.
AIDS (London, England)|March 23, 2016
Early antiretroviral therapy initiation in west Africa has no adverse social consequences: a 24-month prospective studyKévin Jean, Serge Niangoran, Christine Danel, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|April 13, 2004
Impact of vital status investigation procedures on estimates of survival in cohorts of HIV-infected patients from Sub-Saharan AfricaXavier Anglaret, Siaka Toure, Gwénola Gourvellec, et al.
AIDS (London, England)|May 9, 2014
WHO guidelines for antiretroviral therapy in serodiscordant couples in sub-Saharan Africa: how many fit?Gérard Kouamé, Christine Danel, Raoul Moh, et al.
Transactions of the Royal Society of Tropical Medicine and Hygiene|October 2, 2019
Hepatitis B virus activity in untreated hepatitis B e antigen-negative human immunodeficiency virus-hepatitis B virus co-infected patients from sub-Saharan AfricaAnders Boyd, Menan Gerard Kouamé, Laura Houghtaling, et al.
Bulletin of the World Health Organization|August 2, 2008
Early loss of HIV-infected patients on potent antiretroviral therapy programmes in lower-income countriesMartin W G Brinkhof, François Dabis, Landon Myer, et al.
Pageof 17